The effects of the combination therapy of chemotherapy drugs on the fluctuations of genes involved in the TLR signaling pathway in glioblastoma multiforme therapy.

Autor: Norollahi SE; Cancer Research Center and Department of Immunology, Semnan University of Medical Sciences, Semnan, Iran., Yousefzadeh-Chabok S; Guilan Road Trauma Research Center, Trauma Institute, Guilan University of Medical Sciences, Rasht, Iran., Yousefi B; Cancer Research Center and Department of Immunology, Semnan University of Medical Sciences, Semnan, Iran., Nejatifar F; Department of Hematology and Oncology, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran., Rashidy-Pour A; Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. Electronic address: Rashidy-pour@semums.ac.ir., Samadani AA; Guilan Road Trauma Research Center, Trauma Institute, Guilan University of Medical Sciences, Rasht, Iran. Electronic address: a.a.hormoz@gmail.com.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Aug; Vol. 177, pp. 117137. Date of Electronic Publication: 2024 Jul 17.
DOI: 10.1016/j.biopha.2024.117137
Abstrakt: One of the most lethal and aggressive types of malignancies with a high mortality rate and poor response to treatment is glioblastoma multiforme (GBM). This means that modernizing the medications used in chemotherapy, in addition to medicines licensed for use in other illnesses and chosen using a rationale process, can be beneficial in treating this illness. Meaningly, drug combination therapy with chemical or herbal originations or implanting a drug wafer in tumors to control angiogenesis is of great importance. Importantly, the primary therapeutic hurdles in GBM are the development of angiogenesis and the blood-brain barrier (BBB), which keeps medications from getting to the tumor. This malignancy can be controlled if the drug's passage through the BBB and the VEGF (vascular endothelial growth factor), which promotes angiogenesis, are inhibited. In this way, the effect of combination therapy on the genes of different main signaling pathways like TLRs may be indicated as an impressive therapeutic strategy for treating GBM. This article aims to discuss the effects of chemotherapeutic drugs on the expression of various genes and associated translational factors involved in the TLR signaling pathway.
Competing Interests: Declaration of Competing Interest Hope you are doing well. According to the submission of our manuscript which is entitled: “The effects of the combination therapy of chemotherapy drugs on the fluctuations of genes involved in the TLR signaling pathway in glioblastoma multiforme therapy” In this journal, all authors declare that there is no conflict of interest and all the ethical standards considered carefully. Remarkably, all the authors studied and confirmed the final edited version of this manuscript.
(Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: